| Document |
Document Title |
|
WO/2024/084491A1 |
The present invention discloses a process for synthesis of Res metirom and its intermediates thereof. More particularly, the invention discloses process for synthesis of a key intermediate, 6-(4-amino, 2,6-dichlorophenoxy)4- isopropylpyr...
|
|
WO/2024/086699A1 |
The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare stable therapeutic formulations, particularly sustained release formulations, of a variety of active pharmaceutical i...
|
|
WO/2024/086252A1 |
The present disclosure relates to compounds of general formula (I) or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, methods for their preparation, the use of said compounds for use as a medicament, and their use in ...
|
|
WO/2024/086698A1 |
The present invention concerns the use of aprotic polar solvents and an ionization stabilizing agent to prepare stable therapeutic formulations of levothyroxine by dissolving levothyroxine in an aprotic polar solvent system that can then...
|
|
WO/2024/079324A1 |
The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said ...
|
|
WO/2024/079251A1 |
The present invention relates to the field of food supplementation, in particular to the field of nutraceuticals, more in particular to the use of a composition comprising oleuropein. More specifically, the present invention relates to t...
|
|
WO/2024/076995A1 |
Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testoster...
|
|
WO/2024/074705A1 |
The present invention relates to a method of enhancing gene therapy by using an enzyme effective to degrade or digest and/or inhibit or reduce effector function of serum antibodies in the subject. More particularly, the subject is one th...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/068968A1 |
The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and/or luteinizing hormone/ choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of diffe...
|
|
WO/2024/064842A1 |
The present disclosure relates to compositions and methods for improving glucose control, increasing lean body mass, reducing fat mass, treating obesity, diabetes, and/or treating liver dysfunction in a subject. More specifically, the di...
|
|
WO/2024/064779A1 |
The present invention provides a compound of Formula I: wherein R is H or; R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or C...
|
|
WO/2024/062419A1 |
Chinese herbal formulations comprising at least one herb or a component thereof from three or more different classes of Chinese herbs selected from Blood tonifying, Blood moderators, Blood heat coolers, body heat coolers and Yang tonic a...
|
|
WO/2024/060698A1 |
Provided is use of Staphylococcus lentus with an accession number of GDMCC 1.247 in preparing a composition for preventing or treating symptoms of insulin resistance or type 2 diabetes. The strain can significantly reduce the weight gain...
|
|
WO/2024/063348A1 |
A pharmaceutical composition for thyroid protection, according to the present invention, comprises potassium iodide, an excipient and a lubricant, wherein the average particle size of potassium iodide is less than 1.0 mm. The pharmaceuti...
|
|
WO/2024/059951A1 |
This invention provides compound having a structure of Formulas I-VI. Uses of such compounds for treatment of various indications that would benefit from modulation of the androgen receptor, including prostate cancer. Also provided are m...
|
|
WO/2024/059659A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, Y1, Y2, X1, X2, X3, Q1, and Ra are as defined elsewhere herein. Also provid...
|
|
WO/2024/059661A1 |
Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R1, R2, R3, R4, Y1, Y2, X1, X2, L, and Q1 are as defined elsewhere herein. A...
|
|
WO/2024/059665A1 |
Provided herein are compounds of formula (I): (G1-Z1)-L-(G2-Z2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G1, G2, Z1, Z2, and L, are as defined elsewhere herein. Also p...
|
|
WO/2024/051749A1 |
Provided are a polymorph of a GLP-1R agonist compound I, a preparation method therefor, and use thereof. Compared with the free state of the compound I, the polymorph has higher stability and better processability, and is more suitable f...
|
|
WO/2024/052896A1 |
The present subject matter provides a composition for use in the treatment and prevention of neurodegenerative, endocrine and autoimmune diseases that are caused by, or linked to, glutamate/GABA imbalance, and excitotoxicity, the composi...
|
|
WO/2024/052445A1 |
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is the CXCR3 antagonist 1-{(R)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4- (2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazi...
|
|
WO/2024/051787A1 |
Provided are a long-acting acylated insulin derivative and use thereof and a preparation method therefor. The long-acting acylated insulin derivative is formed by connecting a fatty acid side chain to an insulin peptide chain in an acyla...
|
|
WO/2024/046384A1 |
The present invention relates to an antibody specifically binding to a TSHR or an antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, a nucleic acid molecule enc...
|
|
WO/2024/042187A1 |
Disclosed herein are compounds of the formula (I) or a pharmaceutically acceptable salt thereof (I) Wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; R3' and R3" independently represent a hydrogen atom, a met...
|
|
WO/2024/041372A1 |
Provided are a branched polypeptide vector and a variant thereof. The branched polypeptide has a sequence set forth in the following: Xaa1(P2)-Xaa1-Xaa1(P1)-Xaa1-Xaa1(P2), or Xaa1(P1)-Xaa1-Xaa1(P2)-Xaa1-Xaa1(P2)-Xaa1-Xaa1(P1), or Xaa1(P2...
|
|
WO/2024/042152A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; R3' and R3" independently represent a hydrogen atom, a methyl...
|
|
WO/2024/038128A1 |
The present invention relates to compounds of Formulas I to V and la to Va, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment...
|
|
WO/2024/038132A1 |
The present invention relates to compounds of Formulas I to IV, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or preventi...
|
|
WO/2023/031380A9 |
The invention relates to a dosage regime for compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors for use in the treatment of obesity and related conditions.
|
|
WO/2024/038129A1 |
The present invention relates to compounds of Formulas I to V and Ib to Vb, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment...
|
|
WO/2024/039858A1 |
The present disclosure provides compounds that are estrogen receptor modulators (e.g., estrogen receptor agonists, estrogen receptor antagonists, and/or complete estrogen receptor antagonists), and uses thereof.
|
|
WO/2024/037235A1 |
Provided are a polycyclic thyroid hormone β receptor agonist and the use thereof. Specifically, the present invention relates to a compound as represented by formula (1) or a pharmaceutically acceptable form thereof, a pharmaceutical co...
|
|
WO/2024/037532A1 |
Disclosed in the present invention are a salt form and a crystal form of a thienopyrimidinone derivative and a preparation method therefor. Specifically, disclosed are a salt form and a crystal form of a compound of formula (I), and a pr...
|
|
WO/2024/035964A1 |
Featured are compositions and methods for an ovarian implant comprising ovarian support cells. In particular, the disclosure features methods of culturing ovarian support cells for the purpose of implantation into a subject in need there...
|
|
WO/2024/032090A1 |
Disclosed is a method for improving a lipid metabolism function of a subject, comprising administering to the subject a composition comprising an effective amount of β-aminoisobutyric acid or a pharmaceutically acceptable salt, an acid,...
|
|
WO/2024/027621A1 |
Synergistic compositions for improving mineral bioaccessibility comprise lutein, casein phosphopeptide or 1,3-dioleoyl-2-palmitoylglycerol, preferably in combination with one or more of non-digestible oligosaccharides. The compositions c...
|
|
WO/2024/028808A1 |
The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...
|
|
WO/2024/022465A1 |
The present invention provides a human amylin polypeptide analogue comprising an unnatural amino acid and a derivative of the human amylin polypeptide analogue. The human amylin polypeptide derivative obtained by means of introducing an ...
|
|
WO/2024/023572A1 |
The present invention relates to hemotherapy, more particularly to a molecular iodine-enriched purified blood and to its use in the treatment and prevention of several diseases, including cancer. The invention also relates to process for...
|
|
WO/2024/020164A2 |
The present disclosure describes glucocorticoid agonist compounds, their conjugates with binding proteins, pharmaceutical compositions thereof, as well as methods and uses for treating diseases or conditions, such as autoimmune or inflam...
|
|
WO/2024/016072A1 |
The present disclosure relates to methods for reproductive management of mammalian animals using a GnRH antagonist such as Cetrorelix. Specifically, the GnRH antagonist can be used for synchronizing follicular wave emergence in a populat...
|
|
WO/2024/015763A1 |
The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a pregnant mother of a prenatal subject in need thereof, and to pharmaceutical DIPT...
|
|
WO/2024/015762A1 |
The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, and to administering gene therapy to the subject by intr...
|
|
WO/2024/015765A1 |
The present subject matter is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, wherein the DITPA administration reduces triiodothyr...
|
|
WO/2024/008766A1 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...
|
|
WO/2024/005113A1 |
The present invention addresses the problem of providing a novel compound that has a thyroid-stimulating hormone receptor antagonist activity and is useful for the treatment of thyroid-related diseases. The present invention relates to...
|
|
WO/2024/003535A2 |
Disclosed are compounds of the formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof: (I) wherein R1, R2, R3, R4, R5, n, m, and x are as defined herein. Compounds of the invention may be suit...
|
|
WO/2024/003906A1 |
The present invention provides cannabinoid derivatives, pharmaceutical compositions comprising same, and methods of use thereof as medicaments.
|
|
WO/2023/248688A1 |
Provided is a novel testosterone secretagogue. A testosterone secretagogue according to the present invention contains a powder or extract of Paecilomyces tenuipes. This testosterone secretagogue promotes the secretion of testosterone ...
|
